Krishna Institute of Medical Sciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Abhinay Bollineni

Chief executive officer

₹22.0m

Total compensation

CEO salary percentage	77.3%
CEO tenure	5.3yrs
CEO ownership	0.07%
Management average tenure	no data
Board average tenure	2.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Abhinay Bollineni's remuneration changed compared to Krishna Institute of Medical Sciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	₹3b
Mar 31 2024	₹22m	₹17m	₹3b
Dec 31 2023	n/a	n/a	₹3b
Sep 30 2023	n/a	n/a	₹3b
Jun 30 2023	n/a	n/a	₹3b
Mar 31 2023	₹20m	₹15m	₹3b
Dec 31 2022	n/a	n/a	₹3b
Sep 30 2022	n/a	n/a	₹3b
Jun 30 2022	n/a	n/a	₹3b
Mar 31 2022	₹12m	₹12m	₹3b
Dec 31 2021	n/a	n/a	₹3b
Sep 30 2021	n/a	n/a	₹3b
Jun 30 2021	n/a	n/a	₹3b
Mar 31 2021	₹9m	₹9m	₹2b
Dec 31 2020	n/a	n/a	₹2b
Mar 31 2020	₹8m	₹8m	₹1b
Mar 31 2019	₹5m	₹5m	-₹477m

Compensation vs Market: Abhinay's total compensation ($USD260.74K) is below average for companies of similar size in the Indian market ($USD611.49K).

Compensation vs Earnings: Abhinay's compensation has been consistent with company performance over the past year.

CEO

Abhinay Bollineni (36 yo)

5.3yrs

Tenure

₹22,000,000

Compensation

Dr. Abhinay Bollineni serves as Chief Executive Officer of Krishna Institute of Medical Sciences Limited since July 3, 2019 and has been its Executive Director since January 18, 2019. He holds a bachelor’s...

Board Members

Name	Position	Tenure	Compensation	Ownership
Bhaskara Bollineni	Founder	no data	₹38.67m	32.25% ₹ 73.6b
Abhinay Bollineni	CEO & Executive Director	5.8yrs	₹22.00m	0.069% ₹ 157.2m
Anitha Dandamudi	Director of Operations & Wholetime Director	no data	₹5.80m	no data
Saumen Chakraborty	Independent Director	no data	₹3.52m	no data
Yalamanchili Rani	Additional Non-Executive & Independent Director	2.5yrs	₹1.06m	no data
Venkata Jasthi	Independent Director	no data	₹1.06m	no data
Adwik Bollineni	Additional Non-Executive Non-Independent Director	less than a year	no data	0.010% ₹ 23.2m
Ratna Kaza	Independent Director	no data	₹1.06m	no data

2.5yrs

Average Tenure

70yo

Average Age

Experienced Board: 543308's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Krishna Institute of Medical Sciences Management

Management criteria checks 2/4

Key information

Recent management updates

Krishna Institute of Medical Sciences Limited, Annual General Meeting, Aug 29, 2024

Krishna Institute of Medical Sciences Limited Announces Cessation of Rajeswara Rao Gandu as Independent Director

Krishna Institute of Medical Sciences Limited Announces Ceasation of Pankaj Vaish as Independent Director

Krishna Institute of Medical Sciences Limited Appoints Adwik Bollineni as Additional Director

Krishna Institute of Medical Sciences Limited Appoints Adwik Bollineni as Additional Director

Krishna Institute of Medical Sciences Limited Announces Resignation of Shantanu Rastogi as Non-Executive & Non-Independent Director

Recent updates

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired an additional 2.24% stake in KIMS-SUNSHINE Hospitals for approximately INR 400 million.

Krishna Institute of Medical Sciences Limited to Report Q2, 2025 Results on Nov 09, 2024

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired an additional 2.21% stake in KIMS-SUNSHINE Hospitals for approximately INR 365.16 million.

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) Completed the acquisition of Chalasani Hospitals Private Limited.

Price target increased by 7.1% to ₹2,419

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Krishna Institute of Medical Sciences Limited to Report Q1, 2025 Results on Aug 07, 2024

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) entered into agreement to acquire Chalasani Hospitals Private Limited for INR 750 million.

Full year 2024 earnings: EPS and revenues miss analyst expectations

Krishna Institute of Medical Sciences Limited, Annual General Meeting, Aug 29, 2024

Krishna Institute of Medical Sciences Limited to Report Q4, 2024 Results on May 16, 2024

Price target increased by 8.3% to ₹2,327

New minor risk - Financial position

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Krishna Institute of Medical Sciences Limited Announces Cessation of Rajeswara Rao Gandu as Independent Director

Krishna Institute of Medical Sciences Limited to Report Q3, 2024 Results on Feb 03, 2024

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired 5.04% stake in KIMS-SUNSHINE Hospitals for INR 740 million.

Krishna Institute of Medical Sciences Limited Announces Ceasation of Pankaj Vaish as Independent Director

Krishna Institute of Medical Sciences Limited Appoints Adwik Bollineni as Additional Director

Krishna Institute of Medical Sciences Limited Appoints Adwik Bollineni as Additional Director

Krishna Institute of Medical Sciences Limited Announces Resignation of Shantanu Rastogi as Non-Executive & Non-Independent Director

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired an additional 6.86% in Spanv Medisearch Lifesciences Private Limited

Krishna Institute of Medical Sciences Limited to Report Q2, 2024 Results on Nov 07, 2023

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired an additional 5.72% stake in Spanv Medisearch Lifesciences Private Limited for approximately INR 222 million.

Price target increased by 8.0% to ₹2,099

Price target increased by 8.6% to ₹1,826

Full year 2023 earnings: EPS exceeds analyst expectations

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired an additional 2.49% stake in Sarvejana Healthcare Private Limited for INR 350 million.

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired an additional 2.49% stake in Sarvejana Healthcare Private Limited for INR 350 million.

Krishna Institute of Medical Sciences Limited to Report Q1, 2024 Results on Aug 07, 2023

Krishna Institute of Medical Sciences Limited Appoints Mr. Sachin Ashok Salvi as the Chief Financial Officer, Effect from August 01, 2023

Krishna Institute of Medical Sciences Limited, Annual General Meeting, Aug 30, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Krishna Institute of Medical Sciences Limited to Report Q4, 2023 Results on May 18, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Krishna Institute of Medical Sciences Limited to Report Q3, 2023 Results on Feb 09, 2023

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired additional 5.53% stake in Sarvejana Healthcare Private Limited.

Krishna Institute of Medical Sciences Limited Announces Resignation of Mr. Shantanu Rastogi as Director (Non-Executive)

Krishna Institute of Medical Sciences Limited (BSE:543308) acquired 4.07% stake in KIMS Hospital Enterprises Private Ltd for INR 245 million.

Krishna Institute of Medical Sciences Limited (BSE:543308) acquired additional 7.79% stake in Arunodaya Hospitals Private Limited.

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Krishna Institute of Medical Sciences Limited to Report Q2, 2023 Results on Nov 11, 2022

Price target increased to ₹1,509

Krishna Institute of Medical Sciences Limited (BSE:543308) acquired majority stake 51% Spanv Medisearch Lifesciences Private Limited.

Krishna Institute of Medical Sciences Limited (BSE:543308) agreed to acquire 51% Spanv Medisearch Lifesciences Private Limited.

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Krishna Institute of Medical Sciences Limited (BSE:543308) agreed to acquire 51% stake in KIMS Manavata Hospital.

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Krishna Institute of Medical Sciences Limited, Annual General Meeting, Aug 11, 2022

Insufficient new directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Krishna Institute of Medical Sciences Limited to Report Q3, 2022 Results on Feb 10, 2022

Insufficient new directors

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS ₹11.48 (vs ₹3.85 in 1Q 2021)

Investor Director Sandeep Naik has left the company

Investor sentiment improved over the past week

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age